Study of Abituzumab in Combination With Cetuximab and FOLFIRI in Patients With Metastatic Colorectal Cancer.
Status:
Withdrawn
Trial end date:
2021-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of the experimental drug
abituzumab (EMD525797) in combination with cetuximab and FOLFIRI in RAS wild-type,
left-sided, metastatic colorectal cancer patients with high ανβ6 integrin expression.
Phase:
Phase 2
Details
Lead Sponsor:
SFJ Pharmaceuticals X, LTD.
Collaborators:
Academic and Community Cancer Research United AIO-Studien-gGmbH Merck KGaA Merck KGaA, Darmstadt, Germany SFJ Pharmaceuticals, Inc.